In this study, we have analyzed circulating neoplastic cells 
the clinical and laboratory findings. [8] [9] [10] [11] [12] [13] [14] [15] [16] number of neoplastic cells in all the investigated categories.
In this study, we have analyzed circulating neoplastic cells molecule-1 (ICAM-1: CD54) which belongs to the immunoKeywords: B cell lymphoproliferative disorders; immunophenoglobulin superfamily, as well as (4) distilled water. The final product of the dialysis was run to Nodal involvement (number and site of the involved lymph Sepharose 4B gel filtration, and a high molecular-weight node areas) was graded as follows: G1: no lymph node carbohydrate peak was collected. enlargement; G2: one node, or one group of lymph nodes in The PPME preparation started by a mild acid hydrolysis of a localized area; G3: involvement of two or more sites con-H. holstii phosphomannan, then saturated by barium hydroxtiguous along pathways of lymphatic drainage and limited to ide, and the barium salt of high molecular weight PPME was one side of diaphragm (eg neck and axillae); G4: two or more precipitated by ethanol. After the removal of barium by a catnoncontiguous sites of involvement on both sides of diaion exchange resin, a sodium salt was obtained. The acid phragm; and G5: generalized dissemination (bone marrow, hydrolysis resulted in a pentasaccharide phosphonoester spleen and liver involvement were not considered).
(PENT) which was also isolated from the supernatant of barThe histological patterns of bone marrow infiltration were ium precipitation. Prior reduction with sodium borohydride recorded as nodular, interstitial, mixed (nodular and and mild periodate oxidation, PPME and fucoidin were interstitial) and diffuse. The degree of lymphocytosis was derivatized with hexanediamine. regarded as high when there were over 50 × 10 9 /l circulating The b-PPME and b-fucoidin were produced as follows: lymphocytes; lymphocyte doubling time (LDT) less than 12 20 mg of the amino-derivatives of PPME/fucoidin were dismonths was considered a bad prognostic indicator; anemia solved in 550 l phosphate-buffered saline (PBS), and 10 mg (Hb Ͻ11 g/dl) and thrombocytopenia (platelets Ͻ100 × 10 9 /l) of BNHS in 200 l dimethyl-sulfoxide (DMSO). Both solutions were also recorded. The progressive or non-progressive nature were mixed at room temperature, and the mixture was incuof the disease was determined, considering if the patient bated overnight, then precipitated with three volumes of 95% required treatment for active disease. The specificity of L-selectin ligand analogs was tested by precell markers on a FACScan flow cytometer (Becton Dickinson, incubation of CLL cells with LECAM-1, and by saturating the Mountain View, CA, USA). Assays were performed using the binding sites with unconjugated analogs (250 g/ml PPME following McAbs: RFT11 (Prof G Jánossy, Royal Free Hospital, and fucoidin, 30 min, 4°C). Binding of b-PPME was reduced London, UK) for CD2, Leu-3a for CD4, Leu-2a for CD8, Leuwith −79 ± 8% (LECAM-1) and −51 ± 21% (PPME). Preincu-M5 for CD11c, Leu-12 (PE: phycoerythrin conjugated) for bation with LECAM-1 and with non-conjugated fucoidin also CD19, anti-IL-2 for CD25 (all supplied by Becton Dickinson, resulted in a decrease of b-fucoidin binding (−24 ± 30% and Mountain View, CA, USA), UCTH-2 for CD5 (Prof P Beverley, −90 ± 6%, respectively). University College, London, UK), J5 for CD10 (Coulter, Hialeah, FL, USA), OKB22 for CD22 (Ortho, Raritan, NJ, USA),
Immunofluorescence analysis for CD24 (Dr K Kikuchi, Sapporo Medical University School of Medicine, Sapporo, Japan), WR17 for CD37 (Prof JL Smith, In order to detect the adhesion profile specifically on clonal B Southampton University Hospitals, Southampton, UK), GRB1 cells a double labelling with phycoerythrin conjugated CD19 for HLA-DR (Prof F Garrido, General Hospital of Baza, GranMcAb (Becton Dickinson) was applied in CLL cases, while in ada, Spain), FMC7 (Sera-Lab, Crawley Down, Sussex, UK), B-HCL and B-NHL, phycoerythrin-conjugated anti-kappa or ly-7 for CD103 (Dr S Poppema, Cross Cancer Institute, anti-lambda McAb (DAKO) were used. Some of the McAbs Edmonton, Alberta, Canada), HC2 (non-clustered; Dr D Posagainst adhesion molecules such as Leu-8 for CD62L, antinett, Cornell University Medical College, New York, NY, CD11a for LFA-1␣, anti-CD18 for integrin ␤2 chain (Becton USA), SN8 for CD79b (Dr BK Seon, Roswell Park Cancer InstiDickinson) and anti-CD29 for integrin ␤1 chain (Immunotech, tute, Buffalo, NY, USA), anti-IgM, anti-IgA, anti-IgD and antiMarseille, France) were fluorescein-isothiocyanate (FITC) conIgG (DAKO, Copenhagen, Denmark). In a few cases, the jugated, and a double direct immunofluorescence technique immunoalkaline phosphatase (APAAP) technique with antiwas performed. In the case of unconjugated McAbs, such as kappa and anti-lambda reagents (DAKO) was applied on cytoanti-CD49d for VLA ␣-4, anti-CD49e for VLA ␣-5, anti-CD54 spin slides when clonality could not be established by memfor ICAM-1 and anti-CD44 (Immunotech), before the incubrane staining.
bation with the PE-conjugated McAb (anti-CD19 and kappa/lambda) a mouse-serum (1:2000) was applied to block the free binding sites of the primary McAb layer. All the incu- In case of b-PPME and b-fucoidin, an extravidin-FITC conjugate and 3). These differences were statistically significant (P Ͻ 0.001 for CD18 and CDw49d, P Ͻ 0.05 for CD11a and (Sigma, St Louis, MO, USA) was applied to detect the binding sites (control set up: no biotinylated analogs added).
CD29). LFA-1 (CD11a/CD18) was highly expressed in SLVL (Figure 1 ), the differences also being statistically significant for The cut-off point to consider a positive case was when the adhesion molecule was expressed on over 20% of clonal B both the ␣ and ␤ chains when compared to CLL and to HCL (P Ͻ 0.05) ( Table 1) . cells.
The VLA-5 ␣ chain (CD49e) expression was usually low in the majority of the cases regardless of the disease subtypes (10/36, 27% in CLL and 4/17, 23% in the other cases) Statistics (Table 1, Figure 3) .
A positive correlation was found between the expression of Data were analyzed by a two-tailed t test and by the calculation of the Kendall rank correlation coefficients.
␣ and ␤ chains of the LFA-1, VLA-4 and VLA-5 integrins (P Ͻ 0.05) in CLL cases.
Results

Expression of the ICAM-1 (CD54) molecule and hyaluron binding protein (CD44) Expression and function of L-selectins on leukemic B cells
All cases regardless of the disease category expressed CD54. However, the proportion of CD54-positive cells was very variThe number of cases positive with Leu-8 was significantly higher in CLL which includes CLL/PL (20/38, 52% of cases) able and significantly lower (P Ͻ 0.01) in CLL (56 ± 17%, range: 25-97%) compared to non-CLL cases (71 ± 19%, (Figure 1 ) than in other B cell disorders (3/17, 17%) ( Table 1) . Within positive cases, the proportion of cells staining with range: 25-98%) (Figure 3) . Expression of CD44 molecule was also high in all the types Leu-8 was 52 ± 12% (range: 23-81%) in CLL and 48 ± 10% (range: 38-58%) in other cases. The functional activity of Lof diseases, but with no differences among them (Table 1 , Figure 3 ). selectins, the b-PPME binding, correlated well with the Leu-8 expression in CLL and CLL/PL (P Ͻ 0.001 and P Ͻ 0.01, respectively). Among the other B cell diseases, the L-selectin expression and its function was low, particularly, in SLVL (1/7, Adhesion profile of leukemias/lymphomas related to clinical stages and lymph node status 14%) (Figures 1 and 2 , Table 1 ).
In CLL and CLL/PL there was no correlation between the expression of adhesion molecules and clinical stages: conExpression of the LFA-1 (CD11a/CD18) and VLA-4,5 (CD49d,e/CD29) integrins sidering stages A vs B, A vs B + C, and according to Rai 0 vs 1, 2, 3 and 4, or 0 and 1 vs 2, 3 and 4; 0, 1 and 2 vs 3 and 4, or the patterns of lymph node involvement. In contrast The expression of LFA-1 ␣ and ␤ chains and VLA-4 integrins was variable (Table 1) . Overall these integrins were expressed CD18 was expressed on a significantly higher number of CLL cases in stage B, or stages B and C (2/5, 40%, 39-66%, on a higher number of non-CLL cases as follows: CD11a was often positive in NHL and SLVL (12/13, 92%), whereas less 41 ± 19% and 4/10, 40%, 24-66%, 39 ± 19%, respectively) compared to stage A (2/17, 11%, 29-48%, 38 ± 13%) common in patients with primary leukemias: CLL and HCL (10/43, 23%) (Figure 1 ). CD18 and CD49d were rarely (P Ͻ 0.05). A similar correlation was found when the Rai classification was applied comparing stages 1, 2, 3 and 4 expressed in CLL (11/34, 32% and 17/39, 43%, respectively), The most important observation of this study is the demonstration of a reverse expression of L-selectins (as well as func-48%, 38 ± 13%) (P Ͻ 0.05).
tion: b-PPME-binding), VLA-4 integrin, and ICAM-1 in CLL vs non-CLL cases. The LFA-1 integrin showed a variable pattern and the CD44 was expressed on an equally high number of Adhesion profile of leukemias/lymphomas related to some laboratory and clinical parameters cells in all the investigated categories. We have not been able to show a correlation between the expression of these adhesion receptors and the pattern of hematogenous dissemiNeither of the laboratory parameters (lymphocyte count, lymphocyte doubling time, pattern of bone marrow infiltration) nation (see below). Our results showed that half of the CLL cases expressed Lnor progressive vs non-progressive nature of the disease correlated to expression of any adhesion molecules.
selectins, while these were only expressed on small number of cells at a detectable level in the other B cell lymphoproliferative disorders (HCL, SLVL, NHL) (17% of cases). A low expression of L-selectins (Leu-8) has been reported by Hanson Discussion et al, 26 in 11 cases of Leu-M5 (CD11c) positive B-lymphoproliferative disorder which probably included some SLVL, and The leukemias/lymphomas studied represent neoplasias of B cells at different stages of maturation. CLL cells reflect an antithe authors implied that this related to the reduced capacity of the leukemic cells to involve lymph nodes. 26 gen-independent prefollicular state of differentiation, while cells from SLVL, HCL and NHL are thought to be equivalent Both LFA-1 and VLA-4 were expressed on a few cells in a small number of CLL (19 and 33% of cases, respectively), to a subsequent antigen-dependent differentiation. 23 Although the diagnostic criteria of mature B cell leukemias are well whereas VLA-4 (CD49d/CD29) was almost uniformly expressed on leukemic cells from non-CLL cases (HCL, SLVL established, [23] [24] [25] our findings on different pattern of L-selectin and integrin expression offer additional markers for differenand NHL) (77% of cases). These findings are in agreement with Baldini et al, 27 who reported a reduced VLA-4 expression tial diagnosis. in CLL (global expression of VLA-4 was 37.1%), while an CD49e was only seen in a quarter of CLL and non-CLL cases. The lack of detectable integrin ␤1 chains (only 17 positive out opposite reactivity was seen in NHLs (97.1%). Still, some contradictory findings do exist, such as findings reported by of 38 cases) shows that integrin ␤ chain negative CLL cases exist and have a prognostic relevance (see below). De Rossi Mö ller et al, 28 with all the cases from different low grade B cell neoplasms (CLL, HCL, MZL, centroblastic/centrocytic: et al 35 were also able to detect this molecule on the leukemic cells only in 52% of their studied CLL cases. CB/CC and centrocytic: CC) almost unequivocally expressing VLA-4 ␣ chain. Notable differences were also found within
The variable expression of ICAM-1 in CLL ranging from 17-44% in different series 12, 36 is in contrast with the uniform the group of non-CLL cases regarding the expression of ␤2 (CD18) integrins. SLVL and other NHL cases expressed LFA-ICAM-1 positivity of our CLL cases. These differences may relate to the different McAbs 37 and detection systems 1 ␣ and ␤ chain (CD11a/CD18). Whilst CD11a (LFA-1 ␣ chain) was detectable on hairy cells from one case only, albeit used. 12, 15 Some of these studies correlated the expression of ICAM-1 and serum levels of soluble ICAM-1 with the tumor all HCL cases were CD18 (LFA-1 ␤ chain) positive. It is also remarkable that the number of positive B cells with integrin mass. 14, 15 The origin of soluble ICAM-1 is not clear, although it is assumed that it derives from the tumor cells.
14 However, ␤2 chain (CD18) correlated with the LFA-1 ␣ chain (CD11a) expression in CLL and NHL (series which were large enough we considered all our CLL cases positive for ICAM-1 (Ͼ20% of cells expressed the adhesion molecule), being the number to evaluate the correlation statistically). In view of our findings and those reported by others, [29] [30] [31] [32] both the LFA-1 of cells stained with anti-CD54 significantly higher in non-CLL cases than in CLL. This finding is consistent with reported (CD11a/CD18) and Mac-1 (CD11b/CD18) are expressed on a low number of CLL cells, while the complete LFA-1 heteroddata that certain NHLs (follicular lymphomas, Burkitt's lymphoma, multiple myeloma) express ICAM-1 at a high imer is present on a high number of leukemic cells from SLVL and other NHL. On hairy cells, the ␤2-heterodimer is formed level. 10, 38 In our study, CD44 was unequivocally positive in all types by CD18 and CD11c (p150,95) molecules.
33 VLA-5 ␣ chain expression on mature leukemic B cells has been docuof B cell diseases. Estimation of the CD44 density may be relevant in CLL as it seems that CLL patients with intermediate mented, 27 although, according to Pinto et al 34 this molecule is only present on small proportions of cells (25-40%) in a and high CD44 surface density have longer survival than cases with 'dim' CD44 pattern. 16 An interesting aspect of this issue low number of cases of non-CLL. In our study, mature B cell leukemias did not express VLA-5 integrin as the expression of is the variant isoform expression of CD44. Whilst the standard isoform is highly expressed in all lymphoid tissues and low al 46 showed a correlation between a high CD18 expression and longer survival in both low and high grade B cell lymgrade malignant lymphomas as it was seen in our study, high grade malignant lymphomas express several CD44 isoforms, phomas. By contrast, De Rossi et al 12, 16 in a study of 72 CLL patients demonstrated that patients whose cells do not express and some of them indicate a more aggressive phenotype. 39 We have also shown that the biotinylated ligand analog integrin ␤ chains (␤1 − ␤2 − ␤3 − ) show the most favorable clinical features compared to the other groups. molecule, b-PPME -similarly to fluoresceinated analogs such as f-PPME 11, 40, 41 -is a suitable tool to investigate the L-selectin The difficulties to reveal the exact role and real prognostic significance of adhesion molecules in leukemia/lymphoma function. 42 Some studies have correlated the Leu-8 expression and PPME-binding (L-selectin expression and function) of leudissemination can be explained by many facts. The regulatory processes of adhesion molecule expression of normal lymphokemic CLL cells with their avidity to bind lymph node HEVs, and suggested that L-selectins are responsible for the cytes are probably operative on malignant cells as well. Since they are under the regulatory effect of different lymphokines migration of leukemic B lymphocytes from the blood to the lymph nodes. 11, 43 Stauder et al 13 demonstrated that and variable chemical agents, adhesion molecules change their expression dynamically on the cell surface and as a discontinuous lymph node enlargement (hematogenous dissemination) correlates with the ability of CLL cells to bind consequence their expression and function depend on a state of activation/differentiation. Even simple processes such bindto HEVs in an in vitro HEV-binding assay, and that the HEVbinding capacity by the leukemic cells was variable at differing of lymphocytes to endothelial cells (the initial step of hematogeneous dissemination) depends on a battery of receptorent clinical stages. We have not been able to confirm this, 44 as the number of CLL cells bound to HEVs and to PPME-and ligand interactions (reversible rolling, activation, activationdependent adhesion). 6, 7 Moreover, clinical parameters such fucoidin-derivatized polyacrylamide gels is higher at early stages of the disease than at the later stages. 45 In this study, as the number and location of enlarged lymph nodes (pattern of hematogeneous vs lymphogeneous dissemination) depend except CD18, none of the adhesion molecules showed correlation with the clinical stages (Binet, Rai) , with pattern of dison many additional subsequent cell-cell and cell-matrix interactions. 47 These facts explain the failure to correlate the most semination (hematogeneous vs non-hematogeneous), other laboratory parameters (lymphocyte count, LDT, type of bone important clinical and laboratory parameters even with a representative series of adhesion molecules involved in B lymmarrow infiltration), or progression.
CD18 (␤2 chain) was expressed on a significantly higher phocyte-endothelial interaction (L-selectins, different integrins, ICAM-1, CD44). On the other hand, our study has number of leukemic B cells in advanced stages of CLL compared to early stages. In a series of 69 patients, Erikstein et shown that closely related B cell leukemia/lymphomas have
